1.82
Schlusskurs vom Vortag:
$1.84
Offen:
$1.89
24-Stunden-Volumen:
1.10M
Relative Volume:
1.09
Marktkapitalisierung:
$90.41M
Einnahmen:
$300.00K
Nettoeinkommen (Verlust:
$-27.61M
KGV:
-3.1504
EPS:
-0.5777
Netto-Cashflow:
$-22.17M
1W Leistung:
+21.33%
1M Leistung:
+8.33%
6M Leistung:
+51.67%
1J Leistung:
+122.49%
iBio Inc Stock (IBIO) Company Profile
Firmenname
iBio Inc
Sektor
Branche
Telefon
302-355-0650
Adresse
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
IBIO
iBio Inc
|
1.82 | 91.41M | 300.00K | -27.61M | -22.17M | -0.5777 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-05-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-11-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-01-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Eingeleitet | Alliance Global Partners | Buy |
Alle ansehen
iBio Inc Aktie (IBIO) Neueste Nachrichten
Top iBio (IBIO) Competitors 2026 - MarketBeat
iBio (IBIO) director receives 60,000 stock options vesting over 3 years - Stock Titan
Logos Global reports zero ownership in iBio (NASDAQ: IBIO) - Stock Titan
Point72, Steven A. Cohen report 0% in iBio (IBIO) amendment - Stock Titan
EcoR1 and Oleg Nodelman report 1.58M shares in iBio (NASDAQ: IBIO) - Stock Titan
Cormorant (IBIO) reports 3.83M shares, holds near-10% via warrants - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $6 - Moomoo
iBio (NASDAQ: IBIO) — Sirenia/Manager report 11.59M shares, near 10% cap - Stock Titan
Elizabeth Stoner joins iBio (IBIO) board and files initial Form 3 - Stock Titan
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate - Yahoo Finance
IBIO Should I Buy - Intellectia AI
iBio (IBIO) adviser and manager report a 9.99% beneficial stake - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Insider Traders Lose US$19k As iBio Drops - simplywall.st
iBio, Inc. Stock 12‑Month Price Target Raised to $5.53, Implies 244% Upside - TradingView
IBio 3Q Rev $0.00 >IBIO - Moomoo
Intelligent Bio Solutions Reports 46% Revenue Growth in Q3 FY202 - GuruFocus
IBIO Achieves Key Milestones in Obesity Treatment Development - GuruFocus
IBio reports Q3 fiscal year 2026 financial results and provides corporate update - marketscreener.com
iBio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Frazier funds disclose holdings and warrants in iBio (NASDAQ: IBIO) - Stock Titan
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
iBio (IBIO) raises $74.8M in cash and investments while net loss reaches $22.4M - Stock Titan
iBio (Nasdaq: IBIO) widens Q3 loss, boosts cash to fund pipeline into 2028 - Stock Titan
IBio Extends Cash Runway Into 4Q of Fiscal Yr 2028 - Moomoo
TradingKey - TradingKey
Number of shareholders of iBio, Inc. – NASDAQ:IBIO - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
MSN Money - MSN
iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
iBio Strengthens Board with Appointment of Dr. Stoner - TipRanks
Veteran biotech executive joins iBio (NASDAQ: IBIO) board as Class II director - Stock Titan
iBio Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
iBio appoints Elizabeth Stoner to board of directors By Investing.com - Investing.com Australia
iBio appoints Elizabeth Stoner to board of directors - Investing.com
iBio, Inc. Appoints Dr. Elizabeth Stoner to Board of Directors - Quiver Quantitative
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors - The Manila Times
Biotech veteran Elizabeth Stoner joins iBio board ahead of first human trial - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
iBio (NASDAQ: IBIO) substitutes SILV Fund after 876,340‑share transfer - Stock Titan
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO (IBIO) price target increased by 18.73% to 5.47 - MSN
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
IBIO (iBio Inc.) falls 2.37% today after Q1 2026 EPS lands slightly below consensus estimates.Revenue Guidance - Xã Châu Thành
IBIO (iBio Inc.) reports 77.8 percent year over year Q1 2026 revenue growth, shares edge higher.Growth Acceleration - Cổng thông tin điện tử Tỉnh Sơn La
iBio, Inc. 8-K/A Filing Details: Company Information, Address, and Stock Listing (April 8, 2026) - Minichart
Finanzdaten der iBio Inc-Aktie (IBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):